Overview
Sencilia is pioneering next-generation NICU monitoring technology using advanced MEMS sensor architectures to address flow rate errors in pediatric and neonatal intensive care. The company's Rely-V® program focuses on detecting changes in low-flow infusions to prevent adverse drug events in fragile patients.
Key people
In the news
- Yesterday’s MIXER community event came with a proper imec.istart Awards Show, celebrating the startups that raised the bar this year. Here are the 2026 winners… 🥁 🏆 Booming Team Award - Payflip Fastest-growing team. Nominees: VEOWARE SPACE, Cuez, nxgsat 🏆 World Domination Award - VEOWARE SPACE For the startup taking on the world and winning. Nominees: Go Vocal, Cuez 🏆 Impact Catalyst Award - ReVision Implant For real, measurable impact on people, planet or society. Nominees: Puray, Sencilia 🏆 Pay It Forward Award - Aloïs Echard
- We're excited to share the publication of our nationwide nurse focus group study on infusion monitoring in neonatal intensive care, in the Journal of Neonatal Nursing (JNN)! One message came through loud and clear: when delivering medication at ultra-low flow rates, nurses often have limited visibility into whether medication is actually reaching the patient. Hearing this challenge echoed in nurses' firsthand accounts across multiple Dutch NICUs reinforces why we founded Sencilia: to bring more confidence and safety to infusion
- Exciting news! We have been selected to join the 10th Edition of the EIT Health Catapult Programme. EIT Health Catapult is one of Europe’s leading acceleration and competition programmes for health start-ups, connecting innovators with investors, industry experts, and healthcare leaders. We are proud to be part of this year’s cohort and look forward to showcasing our Rely-V® infusion monitoring technology, receiving expert mentoring, and engaging with the European health innovation ecosystem. Discover more about our journey and the
Something wrong or missing? Send an update. Fixed within 24 hours.